

Edgar Filing: AVENTIS - Form 425

AVENTIS
Form 425
February 13, 2004

Filed by Sanofi-Synthelabo
Pursuant to Rule 135 and Rule 425(b) under the
United States Securities Act of 1933,
as amended, and deemed filed pursuant to Rule 14d-2(b)(2) of the
United States Securities Exchange Act of 1934, as amended

Subject Company: Aventis
Commission File No. 001-10378
Date: February 13, 2004

ON FEBRUARY 13, 2004, THE FOLLOWING ADVERTISEMENTS WERE PUBLISHED ON BEHALF
OF SANOFI-SYNTHELABO IN THE ECONOMIST EUROPEAN EDITION.

* * * *

WE REFUSE TO ACCEPT THAT NOT EVERYONE
CAN BENEFIT FROM OUR DISCOVERIES.

[Close-up image of a smiling mongolian woman]

If you had a new medicine that could help eradicate a disease, would you accept to postpone its distribution? No. Because health matters, the coming together of Sanofi-Synthelabo and Aventis will enable us to meet patients' needs more effectively by making new treatments accessible through an extensive global network. Our project will harness our complementary skills to create a leading pharmaceutical group (No.1 in Europe and No.3 worldwide) committed to improving healthcare and capable of driving strong, sustainable and profitable growth.

SANOFI-SYNTHELABO'S OFFER TO AVENTIS'S SHAREHOLDERS
BECAUSE HEALTH MATTERS

This advertisement does not constitute an offer to sell, or an offer to purchase, any securities

www.sanofi-synthelabo.com

* * * *

WE REFUSE TO ACCEPT THAT
WE CANNOT DEVELOP MEDICINES
FOR TOMORROW JUST BECAUSE OF OUR SIZE.

[Image of young girl looking upward]

Out of every 100,000 molecules screened only one becomes a new drug. Research is a major investment: it takes an average of 12 years and 800 million euros to obtain a medicine. That is why teaming up with Aventis will help us deliver more effective solutions to meet patients' needs. Together, we will harness our complementary skills to create a leading pharmaceutical group (No.1 in Europe

Edgar Filing: AVENTIS - Form 425

and No.3 worldwide) committed to improving healthcare and capable of driving strong, sustainable and profitable growth.

SANOFI-SYNTHELABO'S OFFER TO AVENTIS'S SHAREHOLDERS BECAUSE HEALTH MATTERS

This advertisement does not constitute an offer to sell, or an offer to purchase, any securities

www.sanofi-synthelabo.com